Dr. Reddy’s Laboratories
Dr Reddy’s Laboratories on Friday said it has received the establishment inspection report (EIR) from the US health regulator for its active pharmaceutical ingredient manufacturing plant (CTO-6) in Srikakulam, Andhra Pradesh.
The US Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is close, the Hyderabad-based drugmaker said in a statement.
According to the USFDA, VAI means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
On June 7 this year, Dr Reddy’s had said that the US health regulator had issued Form 483 with four observations after inspecting its facility in Srikakulam.
Shares of the company closed 0.42 per cent lower at Rs 6,669.75 apiece on the BSE on Friday.
(Only the headline and image of this report may have been reworked by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First published: September 6, 2024 | 17:23 IS
Disclaimer:
The information contained in this post is for general information purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose.
We respect the intellectual property rights of content creators. If you are the owner of any material featured on our website and have concerns about its use, please contact us. We are committed to addressing any copyright issues promptly and will remove any material within 2 days of receiving a request from the rightful owner.